Table 3

Antimicrobial resistance of multidrug-resistant Escherichia coli
Participant Country of study Resistance profile Antimicrobial Resistance Testing
Amikacin Ampicillin- Sulbactam Aztreonam Cefepime Cefoxitin Ceftazidime Ceftriaxone Cefuroxime Ciprofloxacin Ertapenem Gentamicin Imipenem Levofloxacin Meropenem Moxifloxacin Nitrofurantoin Piperacillin- Tazobactam Tobramycin Trimethoprim- Sulfamethoxazole
6 US MDR S R R S R R R R R S R S R S R S R I R
6 US MDR S R R S R R R R R S R S R S R S R I R
9 US ESBL S R R R I R R R R S S S R S R S S S R
% susceptible by unique isolate per unique participant 100 0 0 50 0 0 0 0 0 100 50 100 0 100 0 100 50 50 0
1 Afghan MDR S R R S R R R R S S S S S S S S I S R
1 Afghan MDR S R R S R R R R S S S S S S S S I S R
2 Afghan ESBL S R R R I R R R R S R S R S R S S R R
3 Afghan ESBL S R R R S R R R S S S S S S S S S S R
3 Afghan ESBL S R R R S R R R S S S S S S S S I S R
4 Afghan ESBL S R R R I R R R S S S S S S S S S S S
5 (PFT 5) Afghan ESBL S R R R S R R R S S S S S S S S S S R
5 (PFT 8) Afghan ESBL S R R R S R R R R S S S R S R S S R R
7 Afghan ESBL S R R R S R R R R S S S R S R I S S R
8 Afghan ESBL S R R R S R R R R S S S R S R S S R R
10 Afghan ESBL S R R R S R R R S S S S S S S I S S R
11 Afghan ESBL S R R R S R R R R S S S R S R S S S R
12 Afghan ESBL S R R R S R R R S S S S S S I S S S R
12 Afghan ESBL S R R R S R R R S S S S S S I S S S R
13 Afghan ESBL S R R R S R R R R S S S R S R S S R R
% susceptible by unique isolate per unique participant 100 0 0 8 75 0 0 0 42 100 92 100 50 100 42 83 92 75 8

MDR- multidrug-resistant; ESBL- Extended spectrum beta-lactamase producing; PFT- pulsed-field type; S-Susceptible; R-Resistant; I-Intermediate.

Vento et al.

Vento et al. BMC Infectious Diseases 2013 13:68   doi:10.1186/1471-2334-13-68

Open Data